moneyheap
REGN · Analysis updated Oct 30, 2026, 10:45 AM ET
Why is Regeneron Pharmaceuticals, Inc. (REGN) stock moving?
Regeneron's profit came in about 25% above forecasts. The stock jumped about 12% to its highest level since 2024 while most of the market fell. Even after the jump, it costs less per dollar of expected profit than its main biotech peers.
News behind the analysis
- Why is Regeneron Pharmaceuticals stock surging today?EPS $20.07 vs $16.06 expected; revenue $5.12B vs $4.54B; Dupixent global sales +35%; $2.2B buyback capacity left; cemdisiran FDA decision upcoming.
- REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of 'Strongest Years Ever' After Q3 Earnings BeatAdjusted EPS +70%; EYLEA HD +62%; Sanofi collaboration revenue +68%; shares at highest since Oct 2024; retail tone bullish.
- Regeneron (NASDAQ:REGN) surprises with strong Q3 2026, stock soarsRevenue beat by 11%, EPS beat by 23.5%; operating margin 40% vs 27.3%; FDA decision for cemdisiran expected next month.
- Regeneron stock: Q3 revenue jumps as Sanofi deal lifts outlookDevelopment balance fully repaid; $1B upfront to be recognized in Q4; legacy EYLEA fell to $400M from $681M.
- Stock Market Today (Oct. 30, 2026): S&P 500 sinks as Amazon, Intel losses shake Wall StreetMarket context: Regeneron among the top gainers after its beat-and-raise while tech sold off.
- AstraZeneca launches $1.5 billion savings plan with Q3 2026 earningsPeer context: AZN revenue +7% and core EPS +19%; outlook unchanged.
In the Daily Standout
- October 30, 2026: the Daily Standout +11.75%